Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiofarmLTS:0HTH 70 Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus rates LTS:0HTH with a GF Score™ of 70/100 and a GF Value™ of lei0.14. The stock has 8 warning signs investors should review. Among 685 Drug Manufacturers companies, Biofarm ranks better than 94.45% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Biofarm's
Operating Income
for the
three
months ended in Jun. 2026 was lei-10.8 Mil. Biofarm's Interest Expense for the
three
months ended in Jun. 2026 was lei-0.0 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Biofarm SA has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Biofarm's Interest Coverage or its related term are showing as below:
LTS:0HTH'
s Interest Coverage Range Over the Past 10 Years
Min: 764.88 Med: 2003.62 Max: 35885
Current: 2076.24
LTS:0HTH's Interest Coverage is ranked better than 94.45% of 685
companies
in the Drug Manufacturers industry
Industry Median: 14
vs LTS:0HTH: 2076.24
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Biofarm Interest Coverage Related Terms
Biofarm Interest Coverage Historical Data
* Premium members only.
The historical data trend for Biofarm's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
LTS:0HTH vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofarm's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofarm Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofarm's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Biofarm's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Biofarm did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Biofarm (LTS:0HTH) has a Interest Coverage of 0 (At Loss) as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Biofarm and its competitors. Over the past decade, Biofarm's Interest Coverage has ranged from 764.88 to 35,885.00. According to the industry distribution chart, Biofarm ranks #38 out of 685 companies in the Drug Manufacturers industry, placing it in the top 5.5%.
Is Biofarm's Interest Coverage too high?
Biofarm's current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 764.88 to a high of 35,885.00. Based on the distribution chart, Biofarm ranks #38 out of 685 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biofarm has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Biofarm's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofarm ranks #38 out of 685 companies for Interest Coverage. This places Biofarm in the top 6% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 14.00. Historically, Biofarm's own Interest Coverage has ranged from 764.88 to 35,885.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 14.00, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Biofarm and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 14.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofarm's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Biofarm (LTS:0HTH) has a current Interest Coverage of 0 (At Loss). The stock's GF Value™ is lei0.14, compared to a current price of lei0.24 — trading 69.3% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Biofarm's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Biofarm (LTS:0HTH), the current Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofarm (LTS:0HTH) Overvalued in 2026?
Based on GuruFocus' analysis, Biofarm stock appears to be overvalued.
The current stock price of lei0.24 is trading 69.3% above its estimated GF Value™ of lei0.14.
Key valuation signals for LTS:0HTH:
Interest Coverage: 0 (At Loss)
GF Value™: lei0.14 vs. price of lei0.24 (69.3% above fair value)
No single metric tells the full story. See the LTS:0HTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
70GF Score
Get the complete analysis for LTS:0HTH
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTH has been successfully added to your 
